We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
e16546 Background: The role of baseline serum CA125 as a prognostic indicator in ovarian cancer is well documented. However, little is known about the impact of change in CA125 on survival after 3 months of therapy. We conducted survival analysis to answer the question "what is the prognostic impact of change in serum CA125 after 3 months of therapy in(More)
  • 1